Picture loading failed.

Target products collectionGo to CYP2A6/CYP2A6 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

Cat No.: GM-Tg-hg-T06455-Ab

Pre-made anti-CYP2A6 benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-CYP2A6 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

The target: CYP2A6, gene name: CYP2A6, also named as CPA6, CYP2A, CYP2A3, CYPIIA6, P450C2A, P450PB. This gene, CYP2A6, encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by phenobarbital. The enzyme is known to hydroxylate coumarin, and also metabolizes nicotine, aflatoxin B1, nitrosamines, and some pharmaceuticals. Individuals with certain allelic variants are said to have a poor metabolizer phenotype, meaning they do not efficiently metabolize coumarin or nicotine. This gene is part of a large cluster of cytochrome P450 genes from the CYP2A, CYP2B and CYP2F subfamilies on chromosome 19q. The gene was formerly referred to as CYP2A3; however, it has been renamed CYP2A6. [provided by RefSeq, Jul 2008].

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.List Price (In USD)Discount Price (In USD)Qty (Quantity)Sum (In USD)
GM-Tg-hg-T06455-Ab-1-1mg51503090
GM-Tg-hg-T06455-Ab-1-10mgInquiryInquiry
GM-Tg-hg-T06455-Ab-1-100mgInquiryInquiry
GM-Tg-hg-T06455-Ab-2-1mg51503090
GM-Tg-hg-T06455-Ab-2-10mgInquiryInquiry
GM-Tg-hg-T06455-Ab-2-100mgInquiryInquiry
GM-Tg-hg-T06455-Ab-xmgInquiryInquiry
Shipping Cost:760.00
Total:



Description

Catalog No.GM-Tg-hg-T06455-Ab-1, GM-Tg-hg-T06455-Ab-2
Products Name Anti-CYP2A6 monoclonal antibody
Formatmab
Target NameCYP2A6
Gene IDCYP2A6
Gene NameCYP2A6
Gene AliasCPA6, CYP2A, CYP2A3, CYPIIA6, P450C2A, P450PB
Protein Sub-locationSecreted Protein/Potential Cytokines
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody
Derivation (species)Mouse
Species ReactivityHuman(H)
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-CYP2A6 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.